Loading clinical trials...
Loading clinical trials...
Cervical intraepithelial neoplasia will be treated with physical low temperature plasma in the plasma cohort compared to watchful waiting in the control cohort. Primary endpoint after 3-6 months: Pathological remission. Secondary endpoint: HPV remission.
The study was completed with Less recruitment as it was planned due to overwhelming study success. The study was published in August 2023. A link has been added to the Reference section.
Age
18 - No limit years
Sex
FEMALE
Healthy Volunteers
No
Department for Women's Health
Tübingen, Germany
Start Date
September 1, 2017
Primary Completion Date
March 31, 2022
Completion Date
March 31, 2022
Last Updated
July 23, 2024
63
ACTUAL participants
CAP treatment
PROCEDURE
Lead Sponsor
University Hospital Tuebingen
NCT04712851
NCT05266898
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions